Accuray (NASDAQ:ARAY) Receives New Coverage from Analysts at

Research analysts at initiated coverage on shares of Accuray (NASDAQ:ARAYGet Rating) in a research report issued on Thursday. The brokerage set a “buy” rating on the medical equipment provider’s stock.

Accuray Price Performance

NASDAQ ARAY opened at $3.64 on Thursday. The company has a debt-to-equity ratio of 3.16, a current ratio of 1.79 and a quick ratio of 1.00. The firm has a market capitalization of $348.53 million, a price-to-earnings ratio of -33.09 and a beta of 1.50. The company has a 50 day simple moving average of $3.06 and a 200-day simple moving average of $2.62. Accuray has a 52-week low of $1.70 and a 52-week high of $3.74.

Institutional Investors Weigh In On Accuray

A number of institutional investors have recently modified their holdings of ARAY. CTC Capital Management LLC purchased a new stake in shares of Accuray during the first quarter worth $30,000. Zebra Capital Management LLC acquired a new position in Accuray in the 1st quarter worth about $37,000. Schonfeld Strategic Advisors LLC raised its stake in shares of Accuray by 47.2% during the 1st quarter. Schonfeld Strategic Advisors LLC now owns 16,300 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 5,227 shares in the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Accuray during the 1st quarter valued at about $54,000. Finally, Bleakley Financial Group LLC bought a new stake in shares of Accuray in the 4th quarter valued at approximately $41,000. Institutional investors and hedge funds own 63.42% of the company’s stock.

About Accuray

(Get Rating)

Accuray, Inc is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy.

Recommended Stories

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with's FREE daily email newsletter.